home / stock / crbu / crbu quote
Last: | $3.39 |
---|---|
Change Percent: | -0.28% |
Open: | $3.6 |
Close: | $3.39 |
High: | $3.6398 |
Low: | $3.365 |
Volume: | 2,506,813 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.39 | $3.6 | $3.39 | $3.6398 | $3.365 | 2,506,813 | 05-17-2024 |
$3.59 | $3.66 | $3.59 | $3.72 | $3.52 | 1,765,841 | 05-16-2024 |
$3.64 | $3.75 | $3.64 | $3.835 | $3.62 | 2,467,232 | 05-15-2024 |
$3.64 | $3.82 | $3.64 | $3.91 | $3.625 | 1,455,843 | 05-14-2024 |
$3.71 | $3.6 | $3.71 | $3.915 | $3.6 | 2,382,321 | 05-13-2024 |
$3.54 | $3.67 | $3.54 | $3.8 | $3.5213 | 1,000,856 | 05-10-2024 |
$3.65 | $3.5 | $3.65 | $3.695 | $3.5 | 1,507,685 | 05-09-2024 |
$3.5 | $3.64 | $3.5 | $3.7 | $3.44 | 2,403,943 | 05-08-2024 |
$3.73 | $3.88 | $3.73 | $3.89 | $3.685 | 1,237,410 | 05-07-2024 |
$3.83 | $3.85 | $3.83 | $3.93 | $3.76 | 1,571,752 | 05-06-2024 |
$3.77 | $3.77 | $3.77 | $3.9 | $3.69 | 1,817,389 | 05-03-2024 |
$3.64 | $3.75 | $3.64 | $3.82 | $3.56 | 2,348,641 | 05-02-2024 |
$3.69 | $3.65 | $3.69 | $3.85 | $3.61 | 1,739,878 | 05-01-2024 |
$3.63 | $3.76 | $3.63 | $3.76 | $3.61 | 1,473,220 | 04-30-2024 |
$3.78 | $3.74 | $3.78 | $3.895 | $3.71 | 1,476,646 | 04-29-2024 |
$3.71 | $3.9 | $3.71 | $3.9 | $3.69 | 1,044,964 | 04-26-2024 |
$3.76 | $3.8 | $3.76 | $3.84 | $3.71 | 1,632,852 | 04-25-2024 |
$3.85 | $4 | $3.85 | $4.04 | $3.8 | 955,214 | 04-24-2024 |
$3.98 | $4 | $3.98 | $4.21 | $3.98 | 926,550 | 04-23-2024 |
$3.99 | $3.89 | $3.99 | $4.075 | $3.8 | 1,384,845 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
2024-05-16 16:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CRBU on May 16, 2024 02:01PM ET. The previous analyst recommendation was Underperform. CRBU was trading at $3.585 at issue of the analyst recommendation. The overall analyst consensus :...
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Pha...